

WHAT IS IT?

RIGENERA is a device specially developed for the clinical application of regenerative procedures using autologous micrografts.
In the same session, the patient is a donor and receiver of micrografts, which allows the receptor area to benefit from the regenerative activity of the cellular content and the growth factors extracted from the donor area.

COMPONENTS

RIGENERA is a patented technology for the safe preparation of micrografts through mechanical disintegration and automatic filtering of any solid tissue.



RIGENERA MACHINE

Is a compact unit that works with the disposable Rigeneracons and operates at a constant speed of approximately 80 rpm.




RIGENERACON

Is a disposable medical device with CE and FDA certification. It contains a stationary stainless steel grid of 2.5ml capacity and it is made up of 100 hexagonal holes. Around each hole there are 6 microblades, with a total of 600 microblades designed to efficiently cut hard and soft tissues without damaging their structure.

WHAT IS IT BASED ON?


It is based on the Tehory of **MICROGRAFT TISSUE**.
By using **HEALTHY HOMOLOGOUS TISSUE (AUTOLOGOUS)** + **RIGENERA** the result is **REGENERATION OF DAMAGED TISSUE**.

CONVENTIONAL MICROGRAFT



1:1 PROPORTION
With 1 cm2 of healthy tissue (biologically homologous) it regenerate 1 cm2 of damaged tissue.

NEW THEORY OF MICROGRAFT




1:20 PROPORTION
With 1 cm2 of healthy tissue (biologically homologous) it regenerate 20 cm2

IF WE USE HOMOLGY REGENERATION

When we extract **healthy connective tissue HOMOLOGOUS** to the damaged tissue that we want to regenerate, **we take advantage of 95% of its:**

-  DIFFERENTIATION CAPACITY
-  POTENTIALITY
-  EFFICIENCY


***HOMOLOGOUS TISSUE**
■ REGENERATION
■ REPAIR



***Homologous Tissue:** Connective tissue biologically equal to the one that needs to be regenerated.

THE RESULT IS 80% REGENERATION AND 20% REPAIR

REGENERATING IS DIFFERENT THAN REPAIRING




Vitiligo Repigmentation

Recent studies suggest that the disease begins with a genetic change in the melanocytes that makes them more susceptible to stress than they normally are. This stress causes the death of the melanocytes and gives rise to antigens. Specific cytotoxic T against melanocytes are generated in the lymphocytes.

WHAT DOES THE MICROGRAFTING OFFER?

- Constitutes an advance supported by multiple studies that demonstrate the advantages of using the melanocytes in the hair bulb with anagenic characteristics. It is done in the form of a micrograft, thanks to the mechanical and filtered tissue disintegration of the pilosebaceous complex.
- In the follicular melanin unit there is one melanocyte for every 5 keratinocytes in the hair bulb, which is much higher than in the unit of epidermal melanin, which has one melanocyte for every 36 keratinocytes.
- Compared with epidermal melanocytes, the anabolic melanocyte are larger, more dendritic, with a more extensive Golgi and a rough endoplasmic reticulum, and produce larger melanosomes.



Melanocytes produce melanin or different pigment granules yellow, red, gray and black. These granules are the ones that provide color to the hair.



ADVANTAGES

- Without cellular cultivation
- Without chemical and biological treatment
- No side effects (autologous)
- Fast and simple procedure (30 minutes)
- No hospitalization / operating room needed
- Only a local anesthetic is necessary
- No extra specialized equipment needed



PROCEDURE

Requirement: Treat only stable lesions (without growth or modification) of at least 2 years.

<p>1</p> <p>Perform chosen procedure for repigmentation of vitiligo</p> <p>De-epidermalization with laser, dermabrasion etc</p>	<p>2</p> <p>The donor sample is obtained by means of a 4 mm punch of the mastoid hairy area</p> <p>With 2 punch of 4 mm is enough to treat an area of 20 cm²</p>
<p>3</p> <p>Process the micrograft by RIGENERA MACHINE</p> <p>Get 1.2 ml. of solution to inject after 2 minutes of processing the biopsied sample.</p>	<p>4</p> <p>Inject the solution intradermally through mesotherapy, creating papillae in the treated area.</p> <p>Use 1 ml syringe luer lock and 30 G needle.</p>

BIBLIOGRAPHY

- S. Mohanty, A. Kumar, J. Dhawan, V. Sreenivas and S. Gupta. *Non-cultured extracted hair follicle outer root sheath cell suspension for transplantation in vitiligo*. Stem Cell Facility, Departments of Dermatology and Venereology and Biostatistics, All India Institute of Medical Sciences, New Delhi 110029, India.
- Bahadoran P, Ortonne J-P. *Classification of surgical therapies for vitiligo*. In: *Surgical Management of Vitiligo* (Gupta S, Olsson M, Kanwar A, Ortonne J-P, eds). Oxford: Blackwell Publishing, 2007; 59–68.
- Vanscheidt W, Hunziker T. *Repigmentation by outer-root-sheath-derived melanocytes: proof of concept in vitiligo and leucoderma*. *Dermatology* 2009; 218:342–3
- Lan CC, Wu CS, Chen GS, Yu HS. *FK506 (tacrolimus) and endo- thelin combined treatment induces mobility of melanoblasts: new insights into follicular vitiligo repigmentation induced by topical tacrolimus on sun-exposed skin*. *Br J Dermatol* 2011.
- Gupta S, Kumar B. *Epidermal grafting in vitiligo: influence of age, site of lesion, and type of disease on outcome*. *J Am Acad Dermatol* 2003; 49:99–104.
- Tobin DJ, Paus R. *Graying: gerontobiology of the hair follicle pigmentary unit*. *Exp Gerontol* 2001; 36:29–54.
- Slominski A, Wortsman J, Plonka PM et al. *Hair follicle pigmentation*. *J Invest Dermatol* 2005; 124:13–21.